These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37997789)

  • 1. Association of
    Ragkousis A; Kazantzis D; Georgalas I; Theodossiadis P; Kroupis C; Chatziralli I
    Semin Ophthalmol; 2024 Apr; 39(3):201-208. PubMed ID: 37997789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
    Spooner K; Fraser-Bell S; Hong T; Chang A
    Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT.
    Hykin P; Prevost AT; Sivaprasad S; Vasconcelos JC; Murphy C; Kelly J; Ramu J; Alshreef A; Flight L; Pennington R; Hounsome B; Lever E; Metry A; Poku E; Yang Y; Harding SP; Lotery A; Chakravarthy U; Brazier J
    Health Technol Assess; 2021 Jun; 25(38):1-196. PubMed ID: 34132192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of laboratory findings and optical coherence tomography biomarkers on response to intravitreal anti-VEGF treatment in patients with retinal vein occlusion.
    Chatziralli I; Kazantzis D; Kroupis C; Machairoudia G; Dimitriou E; Theodossiadis G; Theodossiadis P; Sergentanis TN
    Int Ophthalmol; 2022 Nov; 42(11):3449-3457. PubMed ID: 35538256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline Factors Associated With 6-Month Visual Acuity and Retinal Thickness Outcomes in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Study Report 4.
    Scott IU; VanVeldhuisen PC; Ip MS; Blodi BA; Oden NL; King J; Antoszyk AN; Peters MA; Tolentino M;
    JAMA Ophthalmol; 2017 Jun; 135(6):639-649. PubMed ID: 28492860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcomes of anti-VEGF treatment of macular oedema due to retinal vein occlusions.
    Corazza P; D'Alterio FM; Savastano MC; Kabbani J; Duguid G; Savastano A; Younis S
    Eur J Ophthalmol; 2022 Nov; 32(6):3536-3546. PubMed ID: 35253456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Month 24 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: SCORE2 Report 10: A Secondary Analysis of the SCORE2 Randomized Clinical Trial.
    Scott IU; Oden NL; VanVeldhuisen PC; Ip MS; Blodi BA; Chan CK;
    JAMA Ophthalmol; 2019 Dec; 137(12):1389-1398. PubMed ID: 31600368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-VEGF treatment in branch retinal vein occlusion: a real-world experience over 4 years.
    Rezar S; Eibenberger K; Bühl W; Georgopoulos M; Schmidt-Erfurth U; Sacu S;
    Acta Ophthalmol; 2015 Dec; 93(8):719-25. PubMed ID: 26109209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab.
    Papakostas TD; Lim L; van Zyl T; Miller JB; Modjtahedi BS; Andreoli CM; Wu D; Young LH; Kim IK; Vavvas DG; Esmaili DD; Husain D; Eliott D; Kim LA
    Eye (Lond); 2016 Jan; 30(1):79-84. PubMed ID: 26449196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
    Mitry D; Bunce C; Charteris D
    Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ranibizumab and aflibercept intravitreal injection for treatment naïve and refractory macular oedema in branch retinal vein occlusion.
    Hogg HJ; Di Simplicio S; Pearce MS
    Eur J Ophthalmol; 2021 Mar; 31(2):548-555. PubMed ID: 32009462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Disorganization of Retinal Inner Layers With Visual Acuity Response to Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Secondary to Retinal Vein Occlusion.
    Babiuch AS; Han M; Conti FF; Wai K; Silva FQ; Singh RP
    JAMA Ophthalmol; 2019 Jan; 137(1):38-46. PubMed ID: 30286219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of initial visual acuity on anti-VEGF treatment outcomes in patients with macular oedema secondary to retinal vein occlusions in routine clinical practice.
    Wai KM; Khan M; Srivastava S; Rachitskaya A; Silva FQ; Deasy R; Schachat AP; Babiuch A; Ehlers JP; Kaiser PK; Yuan A; Singh RP
    Br J Ophthalmol; 2017 May; 101(5):574-579. PubMed ID: 27503394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-Vascular Endothelial Growth Factor Treatment Compared with Steroid Treatment for Retinal Vein Occlusion: A Meta-Analysis.
    Patil NS; Hatamnejad A; Mihalache A; Popovic MM; Kertes PJ; Muni RH
    Ophthalmologica; 2022; 245(6):500-515. PubMed ID: 36288721
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Ragkousis A; Kazantzis D; Georgalas I; Theodossiadis P; Kroupis C; Chatziralli I
    Genes (Basel); 2024 May; 15(6):. PubMed ID: 38927649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
    Shalchi Z; Mahroo O; Bunce C; Mitry D
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD009510. PubMed ID: 32633861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison between Ozurdex and intravitreal anti-vascular endothelial growth factor treatment for retinal vein occlusion-related macular edema: A systematic review and meta-analysis of randomized controlled trials.
    Hu Q; Li H; Xu W; Du Y; Ma C; He J
    Indian J Ophthalmol; 2019 Nov; 67(11):1800-1809. PubMed ID: 31638037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline Characteristics and Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema in Participants With Hemiretinal Vein Occlusion Compared With Participants With Central Retinal Vein Occlusion: Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Report 18.
    Scott IU; Oden NL; VanVeldhuisen PC; Ip MS; Blodi BA;
    JAMA Ophthalmol; 2022 May; 140(5):458-464. PubMed ID: 35323843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Visual and Anatomic Outcomes following Cataract Surgery in Patients with Pre-operative Macular Edema Due to Retinal Vein Occlusions Managed with Intravitreal anti-VEGF.
    Starr MR; Mahr MA; Iezzi R; Barkmeier AJ; Bakri SJ
    Semin Ophthalmol; 2020 May; 35(4):205-209. PubMed ID: 32721186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion.
    Pfau M; Fassnacht-Riederle H; Becker MD; Graf N; Michels S
    Ophthalmic Res; 2015; 54(3):150-6. PubMed ID: 26413794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.